ASCO® 2025 Highlights: Presenter Vignette – Erica Mayer
Erica Mayer
MD, MPH, FASCO
Dana-Farber Cancer Institute
517
The TRADE study: A phase 2 trial to assess the tolerability of abemaciclib dose escalation in early-stage HR+/HER2- breast cancer.
Interested in learning more about these abstracts and other trials presented at ASCO® 2025? Be sure to register for one of our licensed Best of ASCO® events in a city near you.
This program has been made possible through unrestricted support from Boehringer Ingelheim, Eli Lilly and Ipsen
